PRECIGEN, INC. Restricted Cash
PRECIGEN, INC. (PGEN) had Restricted Cash of $200.00 million as of 2022-12-31, per its 10-Q filed 2023-11-09.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCash · last filed 2024-03-19
- 2022-12-31: Restricted Cash $200.00M.
- 2022-08-18: Restricted Cash $200.00M.
| Period end | Restricted Cash |
|---|---|
| 2022-12-31 | $200.00M 10-Q · filed 2023-11-09 |
| 2022-08-18 | $200.00M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |